| Allakos is a clinical stage biotechnology company. Co. is developing AK002, its wholly owned monoclonal antibody, for the treatment of various mast cell and eosinophil related diseases. AK002 selectively targets both mast cells and eosinophils, two types of white blood cells that are distributed in the body and play a central role in the inflammatory response. Inappropriately activated mast cells and eosinophils have been identified as key drivers in a number of severe diseases affecting the gastrointestinal tract, eyes, skin, lungs and other organs. As such, AK002 has the potential to treat a number of severe diseases. We show 12 historical shares outstanding datapoints in our ALLK shares outstanding history coverage, used to compute ALLK market cap on those dates.|
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing ALLK market cap history over the course of time is important for investors
interested in comparing ALLK's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of ALLK versus a peer is one thing; comparing
ALLK market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like ALLK can fluctuate over the course of history.
With this page we aim to empower investors researching ALLK by allowing them to research the ALLK market cap history.